Articles

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Immuno-Hématologie Department, Hôpital Saint-Louis/Centre d'Investigations Cliniques, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, France
Cherkassy Regional Oncology Dispensary, Cherkassy, Ukraine
Oddzial Hematologiczny ZSM, Chorzow, Poland
Kiev BMT Center, Ukraine
Hopital Huriez, CHRU, Lille, France
Janssen Research & Development, Beerse, Belgium
Janssen Research & Development, Raritan, NJ, USA
Janssen Research & Development, High Wycombe, Buckinghamshire, UK
Janssen Research & Development, Beerse, Belgium
University Hospital, Nantes, France
Vol. 97 No. 12 (2012): December, 2012 https://doi.org/10.3324/haematol.2012.067793